Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher, CHLA Team on Pediatric Cancer NGS Panel

NEW YORK (GenomeWeb) – Children's Hospital Los Angeles and Thermo Fisher Scientific announced today that they will partner to develop a next-generation sequencing-based gene panel for pediatric cancer research.

The assay, a targeted DNA and RNA sequencing-based gene panel, would target biomarkers — mutations, amplifications, and gene expression of more than 1,000 gene fusion variants — associated with childhood cancers. The panel will also include almost all somatic genetic alterations identified in the literature to date as having an association with pediatric cancers.

The panel will use Thermo's Ion Torrent NGS platform and Ion AmpliSeq technology, which requires as little as 10 nanograms of DNA and RNA from fixed, fresh, or frozen tumor samples. The results would be used to help researchers better understand pathogenesis and could lead to the development of new therapies, the partners said in a statement.

CHLA will contribute the expertise of a team of pathologists and lab researchers from its Center for Personalized Medicine, and clinicians and pediatric cancer investigators at its Children's Center for Cancer and Blood Diseases.

"We anticipate the pediatric panel to be of great value to clinical researchers dedicated to improving outcomes in childhood cancer, providing a tool with the potential to further advance personalized cancer treatment," Alan Wayne, director of the Children's Center for Cancer and Blood Diseases, said in a statement. "Such personalized cancer care is of considerable benefit to patients and practitioners as we work to develop genomically targeted therapies."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.